UPSC Prelims Practice Questions — Aurobindo Pharma gets U.S. FTC nod to buy Lannett Company
Q1. As a condition for clearing Aurobindo Pharma's 2026 acquisition of Lannett Company, the U.S. Federal Trade Commission required the divestiture of how many generic drug products?
- A. Two
- B. Three
- C. Four
- D. Six
Q2. Aurobindo Pharma's acquisition of Lannett Company deepens its presence in which country's market — the world's largest market for generic drugs?
- A. Germany
- B. China
- C. India
- D. United States
Q3. Which U.S. authority granted the conditional antitrust clearance for Aurobindo Pharma's acquisition of Lannett Company in June 2026?
- A. U.S. Food and Drug Administration (USFDA)
- B. Federal Trade Commission (FTC)
- C. Antitrust Division of the Department of Justice
- D. U.S. Securities and Exchange Commission (SEC)
Q4. Under the U.S. FTC consent order accompanying the Aurobindo–Lannett deal, the four divested generic products are required to be sold to which company?
- A. Quagen Pharmaceuticals
- B. Sun Pharmaceutical Industries
- C. Lupin Limited
- D. Dr. Reddy's Laboratories
Q5. With reference to the 2026 Aurobindo Pharma–Lannett Company transaction, consider the following statements:
1. Aurobindo Pharma, the acquirer, is headquartered in Hyderabad, India.
2. Lannett Company, the target firm, is based in Pennsylvania in the United States.
3. The generic products ordered to be divested under the FTC consent order are to be acquired by Quagen Pharmaceuticals.
Which of the statements given above is/are correct?
- Aurobindo Pharma, the acquirer, is headquartered in Hyderabad, India.
- Lannett Company, the target firm, is based in Pennsylvania in the United States.
- The generic products ordered to be divested under the FTC consent order are to be acquired by Quagen Pharmaceuticals.
- A. 1 and 2 only
- B. 2 and 3 only
- C. 1 and 3 only
- D. 1, 2 and 3